lasofoxifene
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute. — Wikipedia
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2001 (NCT00141323)
Timeline
Indications
Mechanism of action
- Estrogen receptorAGONIST
Estrogen receptor agonist
- Estrogen receptorMODULATOR
Estrogen receptor modulator
Activates some estrogen pathways and blocks other estrogen pathways.
Chemistry & pharmacology
SMILES
Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1- Mol. weight
- 413.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaLasofoxifene ↗
- ChEMBLCHEMBL328190 ↗
Also known as
- cis-1r-(4'-pyrrolidinoethoxyphenyl)-2s-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt
- (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol
- (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol
- (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol
- cp 336156
- cp-336156
- cp-336,156
- cp-336,156
- fablyn
- las estrogen receptor modulator
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene
- lasofoxifene hydrochloride
- lasofoxifene tartrate
- lasofoxifene tartrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06197568 | Phase 1/Phase 2 (Phase 2) | May 31, 2024 | Azure Biotech Inc. |
| NCT05696626 | Phase 3 | Oct 31, 2023 | Sermonix Pharmaceuticals Inc. |
| NCT04432454 | Phase 2 | Jul 31, 2020 | Sermonix Pharmaceuticals Inc. |
| NCT03781063 | Phase 2 | May 31, 2019 | Accelovance, Sermonix |
| NCT00674453 | Phase 2 | Sep 1, 2004 | Ligand Pharmaceuticals, Pfizer |
| NCT00143273 | Phase 2 | Jun 1, 2004 | Ligand Pharmaceuticals, Pfizer |
| NCT00163137 | Phase 3 | May 1, 2003 | Ligand Pharmaceuticals, Pfizer |
| NCT00141323 | Phase 3 | Nov 1, 2001 | Ligand Pharmaceuticals, Pfizer |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | For profit | 4 | 4 | 2 | 2001 |
| Pfizer | For profit | 4 | 0 | 2 | 2001 |
| Sermonix Pharmaceuticals Inc. | For profit | 2 | 2 | 2 | 2020 |
| Accelovance | For profit | 1 | 0 | 1 | 2019 |
| Azure Biotech Inc. | For profit | 1 | 1 | 1 | 2024 |
| Sermonix | For profit | 1 | 1 | 1 | 2019 |